Provenge Panel's Uncertainty Was More Persuasive To FDA Than Its Vote
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA found the uncertainty expressed by the advisory committee reviewing Dendreon’s Provenge to be a better guide for regulatory action than the panel’s numerical vote supporting approval, according to the FDA review documents for the first autologous cancer vaccine.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: